Cadrenal Therapeutics acquires eXIthera's Factor XIa inhibitors for up to $15M in milestones

Cadrenal Therapeutics, Inc.

Acquires frunexian (Phase 2-ready IV FXIa) and EP-7327 (IND-ready oral FXIa) from eXIthera.
Total contingent milestone payments up to $15M plus royalties on global sales; $50K cash paid at closing.
Deal closed September 12, 2025; Cadrenal now sole developer of both a VKA (tecarfarin) and FXIa inhibitors.
Plans Phase 2 study for frunexian in complex cardiac surgery with first patient expected in 1Q27.
eXIthera to receive 2% royalty on net sales outside China and 50% of sublicense royalties from Haisco.

item 1.01item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.